A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases

A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases

Author Sato, J. O. Google Scholar
Sallum, A. M. E. Google Scholar
Ferriani, Virginia Paes Leme Autor UNIFESP Google Scholar
Marini, R. Google Scholar
Sacchetti, S. B. Google Scholar
Okuda, E. M. Google Scholar
Carvalho, J. F. Google Scholar
Pereira, R. M. R. Google Scholar
Len, Claudio Arnaldo Autor UNIFESP Google Scholar
Terreri, Maria Teresa Ramos Ascensão Autor UNIFESP Google Scholar
Lotufo, S. A. Google Scholar
Romanelli, P. R. Google Scholar
Ramos, V. C. S. Google Scholar
Hilário, Maria Odete Esteves Autor UNIFESP Google Scholar
Silva, C. A. Google Scholar
Corrente, J. E. Google Scholar
Saad-Magalhaes, C. Google Scholar
Rheumatol Comm Sao Paulo Paediat S Google Scholar
Institution Univ Estradual Paulista
Universidade de São Paulo (USP)
Universidade Estadual de Campinas (UNICAMP)
Fac Ciencias Med Santa Casa Sao Paulo
Universidade Federal de São Paulo (UNIFESP)
Hosp Municipal Infantil Menino Jesus
PUC Sao Paulo
Abstract ObjectiveTo describe onset features, classification and treatment of juvenile dermatomyositis (JDM) and juvenile polymyositis (JPM) from a multicentre registry.MethodsInclusion criteria were onset age lower than 18 years and a diagnosis of any idiopathic inflammatory myopathy (IIM) by attending physician. Bohan & Peter (1975) criteria categorisation was established by a scoring algorithm to define JDM and JPM based oil clinical protocol data.ResultsOf the 189 cases included, 178 were classified as JDM, 9 as JPM (19.8: 1) and 2 did not fit the criteria; 6.9% had features of chronic arthritis and connective tissue disease overlap. Diagnosis classification agreement occurred in 66.1%. Medial? onset age was 7 years, median follow-up duration was 3.6 years. Malignancy was described in 2 (1.1%) cases. Muscle weakness occurred in 95.8%; heliotrope rash 83.5%; Gottron plaques 83.1%; 92% had at least one abnormal muscle enzyme result. Muscle biopsy performed in 74.6% was abnormal in 91.5% and electromyogram performed in 39.2% resulted abnormal in 93.2%. Logistic regression analysis was done in 66 cases with all parameters assessed and only aldolase resulted significant, as independent variable for definite JDM (OR=5.4, 95%CI 1.2-24.4, p=0.03). Regarding treatment, 97.9% received steroids; 72% had in addition at least one: methotrexate (75.7%), hydroxychloroquine (64.7%), cyclosporine A (20.6%), IV immunoglobulin (20.6%), azathioprine (10.3%) or cyclophosphamide (9.6%). In this series 24.3% developed calcinosis and mortality rate was 4.2%.ConclusionEvaluation of predefined criteria set for a valid diagnosis indicated aldolase as the most important parameter associated with de, methotrexate combination, was the most indicated treatment.
Keywords Idiopathic inflammatory myopathy
juvenile dermatomyositis
juvenile polymyositis
methotrexate
steroids
Language English
Date 2009-11-01
Published in Clinical And Experimental Rheumatology. Pisa: Clinical & Exper Rheumatology, v. 27, n. 6, p. 1031-1038, 2009.
ISSN 0392-856X (Sherpa/Romeo, impact factor)
Publisher Clinical & Exper Rheumatology
Extent 1031-1038
Origin http://www.clinexprheumatol.org/article.asp?a=7
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000274264700026
URI http://repositorio.unifesp.br/11600/43323

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account